Eli Lilly
Healthcare
Eli Lilly Cuts Zepbound Price by 50% for Self-Pay Patients
Eli Lilly has unveiled a new program aimed at making its weight-loss drug, Zepbound, more accessible to self-pay patients by offering it at...
Healthcare
FDA Greenlights Eli Lilly’s Alzheimer’s Drug Donanemab
On Tuesday, the Food and Drug Administration (FDA) granted approval for Eli Lilly’s Alzheimer’s drug, donanemab, marking a significant milestone in the treatment...
Healthcare
Zealand Pharma Shares Surge 17% on Positive Drug Trial
Shares of Zealand Pharma soared by over 17% on Friday following the announcement of positive trial results for petrelintide, a potential competitor to...
Healthcare
Eli Lilly’s Zepbound Reduces Sleep Apnea in Obese Adults
Eli Lilly’s Zepbound, a weight loss drug, showed promise in treating sleep apnea in obese adults, the company announced Wednesday. Results from late-stage...
